Linked Life Data

15603188

Source:http://linkedlifedata.com/resource/pubmed/id/15603188

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2004-12-17
pubmed:abstractText
Based on the observation that viral infection results in the presentation of virus-specific peptides in association with both MHC Class I and MHC Class II on the surface of infected cells, strategies have been designed to use recombinant viruses carrying tumour-associated antigen (TAA) genes as immunization vehicles to elicit tumour-specific immune responses. I report here on results from phase I clinical studies based on a canarypox viral vector system expressing TAAs of interest. Clinical studies conducted in patients with colorectal cancer to evaluate ALVAC-CEA, ALVAC-KSA, or ALVAC-p53 candidate vaccines have shown that this approach is safe and can induce tumour-specific responses. Additional clinical studies evaluating candidate vaccines against melanoma, targeting either the gp100, Mage 1 or Mage 3 molecules are in progress. On the basis of our results and in the context of parallel studies being conducted with other viral systems, the characteristics of an ideal viral vector system, as it applies to therapeutic cancer vaccination, are discussed.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1424-6074
pubmed:author
pubmed:issnType
Print
pubmed:volume
116
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
117-22; discussion 133-43
pubmed:dateRevised
2006-4-21
pubmed:meshHeading
pubmed:year
2004
pubmed:articleTitle
Recombinant cancer vaccines based on viral vectors.
pubmed:affiliation
Aventis Pasteur, Campus Mérieux, Marcy l'Etoile, France. philippe.moingeon@aventis.com
pubmed:publicationType
Journal Article